PAI Pharma: Nexus Pharmaceuticals Acquisition Adds Over 20 Hospital Injectable Products

PAI Pharma has acquired Nexus Pharmaceuticals, expanding its portfolio of injectable medicines used in critical care, oncology and other hospital settings.

The transaction adds more than 20 commercial hospital injectable products, customer relationships and development expertise to PAI’s growing sterile pharmaceutical business.

PAI, a portfolio company of Olympus Partners, develops, manufactures and markets oral liquid medicines, ready-to-use sterile injectables and other hospital-focused products.

The acquisition follows its purchase of Nivagen, which added aseptic manufacturing capabilities in Sacramento. Together, the transactions support PAI’s strategy of building a broader essential medicines portfolio and increasing its presence in hospital markets.

Nexus specializes in complex injectable products, including therapies that have historically experienced supply shortages. Its business combines pharmaceutical development and analytical capabilities with contract manufacturing relationships and established U.S. hospital customers.

Those capabilities complement PAI’s ready-to-dose oral liquid products and expanding sterile injectable offering.

The acquisition broadens both the range of medicines PAI can offer and the commercial relationships through which it reaches healthcare providers.

The company identified domestic manufacturing investment as an important part of that strategy. Nivagen’s manufacturing infrastructure and Nexus’s product portfolio bring different capabilities to the combined platform: production capacity on one side and development and commercialization experience on the other.

Headquartered in Parsippany, New Jersey, PAI serves customers requiring oral liquid, sterile and ready-to-use dosage forms.

The transaction continues its effort to combine those categories within a larger hospital-oriented pharmaceutical business.

William Blair served as PAI’s exclusive advisor, while Kirkland & Ellis provided legal counsel. Proskauer Rose served as legal counsel to Nexus.

The announcement centers on portfolio expansion and complementary capabilities, with the acquired injectable products adding to PAI’s existing manufacturing and commercialization activities.